Illumina (NASDAQ:ILMN) Director Keith Meister Sells 299,336 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 299,336 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the sale, the director directly owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. This trade represents a 17.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Illumina Stock Up 2.9%

Shares of NASDAQ ILMN traded up $6.16 during trading on Friday, hitting $219.40. 1,917,079 shares of the company traded hands, compared to its average volume of 2,061,622. The firm has a market capitalization of $33.13 billion, a price-to-earnings ratio of 40.93, a P/E/G ratio of 3.00 and a beta of 1.45. The business’s fifty day moving average is $188.01 and its 200 day moving average is $152.44. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $220.43.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm posted $1.19 EPS. Illumina’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Institutional Trading of Illumina

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Greenspring Advisors LLC purchased a new position in shares of Illumina during the 2nd quarter valued at about $264,000. Nykredit A S purchased a new position in shares of Illumina during the second quarter worth approximately $11,370,000. B. Metzler seel. Sohn & Co. AG lifted its holdings in shares of Illumina by 2.7% in the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 5,587 shares of the life sciences company’s stock worth $982,000 after acquiring an additional 146 shares during the last quarter. Symphony Financial Ltd. Co. bought a new stake in shares of Illumina in the 2nd quarter worth approximately $262,000. Finally, Proficio Capital Partners LLC purchased a new stake in shares of Illumina in the 2nd quarter valued at $941,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of a number of research analyst reports. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Guggenheim raised their price target on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Royal Bank Of Canada lifted their price target on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, TD Cowen increased their price objective on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.